Dicot Pharma is conducting preparations ahead of the planned phase 2b clinical study with its drug candidate LIB-01, developed as a new treatment concept for erectile dysfunction.

Today, the company announces that a tablet formulation with favorable characteristics and stability for use in clinical studies has been successfully developed from a previous oral formulation. This week, manufacturing of tablets with the active substance and placebo for the phase 2b study has begun. The plan is to initiate the clinical study in the second half of 2026.

“It’s a great achievement that we have now been able to develop and start the manufacturing of LIB-01 as a well-functioning tablet ahead of the phase 2b study. The switch to tablet formulation is well-timed in the development process, from both regulatory and investment perspectives. It reduces the project’s risk level and gives us a distinct advantage in future commercial tablet development,” says Elin Trampe, CEO of Dicot Pharma.